Recent studies have successfully utilised fluorescence-, radionuclide- and MNP-labelled HSP70-targeting tools, including the full-length antibody cmHSP70.1, Fab fragment and tumour-penetrating peptide (TPP), for fluorescence, positron emission tomography (PET), computed tomography (CT) and magnetic resonance imaging (MRI) in preclinical models. Here, HSPA1A is linked to neoplasm.